Venglustat in GBA1-related Parkinson's disease

Lancet Neurol. 2024 Feb;23(2):137. doi: 10.1016/S1474-4422(23)00455-6.

Authors

Ari Zimran¹, Shoshana Revel-Vilk¹, Michal Becker-Cohen², Majdolen Istaiti³, Arndt Rolfs⁴

Affiliations

¹ Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
² Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
³ Gaucher Unit, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: [email protected].
⁴ Medical Faculty, University of Rostock, Rostock, Germany; RCV Rare Disease GmbH, Berlin, Germany.

PMID: 38267177
DOI: 10.1016/S1474-4422(23)00455-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carbamates*
Humans
Parkinson Disease* / drug therapy
Parkinson Disease* / genetics
Quinuclidines*

Substances

venglustat
Carbamates
Quinuclidines